VIDEO: Bimekizumab efficacious in severe psoriasis, may increase yeast infection risk

ByDavid Statman

Fact checked byKristen Dowd

In this Healio exclusive video, Steven R. Feldman, MD, PhD, discussed study results presented at the American Academy of Dermatology Annual Meeting examining bimekizumab in the treatment of psoriasis.

Feldman, professor of dermatology, pathology and social sciences and health policy at Wake Forest University School of Medicine, discussed safety data into bimekizumab (Bimzelx, UCB) for plaque psoriasis, which showed that the interleukin-17 blocker works quickly and effectively, with the drawback of added risk for yeast infections.

“You get greater efficacy for the skin and the joints. It works really fast,” Feldman said, adding it may currently be the fastest acting drug in treating severe psoriasis. “And the cost is possibly getting a yeast infection for which you might need a Diflucan [fluconazole, Pfizer] pill.”

Published by:

Sources/Disclosures

Collapse

Source: Healio Interview

Disclosures: Feldman reports receiving research, speaking and/or consulting support from AbbVie, Accordant, Almirall, Alvotech, Amgen, Arcutis, Arena, Argenx, Biocon, Boehringer Ingelheim, Bristol Myers Squibb, Caremark, Celgene, Dermavant, Eli Lilly and Company, Eurofins, Forte, Galderma, GlaxoSmithKline/Stiefel, Helsinn, Informa, Janssen, LEO Pharma, Menlo, Merck & Co., Mylan, Micreos, National Biological Corporation, National Psoriasis Foundation, Novan, Novartis, Ono, Ortho Dermatology, Pfizer, Qurient, Regeneron, Samsung, Sanofi, Sun Pharma, Teladoc, UCB, UpToDate and vTv Therapeutics. He also reports being the founder and part owner of Causa Research and holding stock in Sensal Health.

Take Homes in Psoriasis

Read more

VIDEO: Bimekizumab efficacious in severe psoriasis, may increase yeast infection risk

Related Content